FluroTest Systems Ltd. Releases White Paper on the Evolving Role of Antigen Testing in the COVID-19 Pandemic Response

CALGARY, Alberta, Dec. 03, 2020 (GLOBE NEWSWIRE) — FluroTech Ltd. (TSXV: TEST) (OTCQB: FLURF), (“FluroTech” or “the Company”) is pleased to announce that FluroTest Systems Ltd. (“FluroTest”) today released a white paper titled “The Evolving Role of Antigen Testing in the COVID-19 Pandemic Response.”

The report reviews the two basic types of diagnostic tests exist for SARS-CoV-2 virus detection, for which the US Food and Drug Administration (FDA) has issued Emergency Use Authorizations (EUAs):

  • Polymerase chain reaction (PCR) tests—also referred to as reverse transcription PCR (RT-PCR) tests—use a laboratory-based molecular approach to detect genetic material (ribonucleic acid, or RNA) from the virus in a nasal or throat swab or in saliva.
  • Antigen tests, which may be performed at the point of care, detect specific proteins on or within the virus by testing a nasal swab or saliva sample.

While both provide diagnostic value and serve specific functions in the management of the pandemic, their relative roles and utility may be changing as innovations are introduced and test performance, capacity, and accessibility increase.